[SCHEDULE 13G] South Bow Corporation SEC Filing
FMR LLC (parent holding company for Fidelity) and its controlling person Abigail P. Johnson filed Amendment No. 9 to Schedule 13G on 08 Aug 2025 for Taysha Gene Therapies Inc. (TSHA).
- Beneficial ownership: 15,627,821.87 common shares, representing 6.2 % of the outstanding class as of 30 Jun 2025.
- Control rights: Sole voting power over 15,622,332 shares and sole dispositive power over the full 15.628 million; no shared voting or dispositive authority is reported.
- Filing status: Report made under Rule 13d-1(b) as a parent holding company/HC; ownership is held in the ordinary course of business without intent to influence control.
- The amendment keeps FMR above the 5 % reporting threshold, signalling continued material institutional exposure to TSHA.
FMR LLC (societ脿 madre di Fidelity) e la sua controllante Abigail P. Johnson hanno presentato il Modifica n. 9 al Schedule 13G l'08 agosto 2025 per Taysha Gene Therapies Inc. (TSHA).
- Propriet脿 effettiva: 15.627.821,87 azioni ordinarie, pari al 6,2% della classe in circolazione al 30 giugno 2025.
- Diritti di controllo: Potere di voto esclusivo su 15.622.332 azioni e potere dispositive esclusivo sull'intero ammontare di 15,628 milioni; non 猫 segnalata alcuna autorit脿 condivisa di voto o dispositiva.
- Stato della comunicazione: Segnalazione effettuata ai sensi della Regola 13d-1(b) come societ脿 madre/holding company; la propriet脿 猫 detenuta nell'ordinaria attivit脿 commerciale senza intento di influenzare il controllo.
- La modifica mantiene FMR sopra la soglia di segnalazione del 5%, indicando un'esposizione istituzionale significativa e continuativa a TSHA.
FMR LLC (compa帽铆a matriz de Fidelity) y su persona controladora Abigail P. Johnson presentaron la Enmienda No. 9 al Schedule 13G el 08 de agosto de 2025 para Taysha Gene Therapies Inc. (TSHA).
- Propiedad beneficiaria: 15,627,821.87 acciones comunes, representando el 6.2% de la clase en circulaci贸n al 30 de junio de 2025.
- Derechos de control: Poder exclusivo de voto sobre 15,622,332 acciones y poder exclusivo dispositvo sobre el total de 15.628 millones; no se reporta autoridad compartida de voto o dispositiva.
- Estado de la presentaci贸n: Informe realizado bajo la Regla 13d-1(b) como compa帽铆a matriz/holding; la propiedad se mantiene en el curso ordinario del negocio sin intenci贸n de influir en el control.
- La enmienda mantiene a FMR por encima del umbral de reporte del 5%, se帽alando una exposici贸n institucional material y continua a TSHA.
FMR LLC (Fidelity鞚� 氇殞靷�)鞕� 攴� 歆�氚办瀽 Abigail P. Johnson電� 2025雲� 8鞗� 8鞚� Taysha Gene Therapies Inc. (TSHA)鞐� 雽�頃� Schedule 13G 靾橃爼鞎� 9順�毳� 鞝滌稖頄堨姷雼堧嫟.
- 鞁れ 靻岇湢甓�: 2025雲� 6鞗� 30鞚� 旮办 氤错喌欤� 15,627,821.87欤茧, 氚滍枆 欤检嫕鞚� 6.2%鞐� 頃措嫻頃╇媹雼�.
- 韱奠牅 甓岉暅: 15,622,332欤检棎 雽�頃� 雼弲 鞚橁舶甓岅臣 鞝勳泊 1,562毵� 8觳� 欤检棎 雽�頃� 雼弲 觳橂秳 甓岉暅鞚� 氤挫湢頃橂┌, 瓿惦彊 鞚橁舶甓岇澊雮� 觳橂秳 甓岉暅鞚� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.
- 鞁犼碃 靸來儨: Rule 13d-1(b)鞐� 霐半澕 氇殞靷�/歆赌欤柬殞靷�搿滌劀 鞁犼碃霅橃棃鞙茧┌, 靻岇湢甓岇潃 靷梾鞚� 鞝曥儊鞝侅澑 瓿检爼鞐愳劀 氤挫湢霅橃棃瓿� 韱奠牅鞐� 鞓來枼鞚� 氙胳範 鞚橂弰臧� 鞐嗢姷雼堧嫟.
- 鞚措矆 靾橃爼鞎堨溂搿� FMR鞚� 5% 氤搓碃 旮办靹犾潉 鞙犾頃橃棳 TSHA鞐� 雽�頃� 欷戩殧頃� 旮瓣磤 韴瀽 雲胳稖鞚� 瓿勳啀霅潉 雮橅儉雰呺媹雼�.
FMR LLC (soci茅t茅 m猫re de Fidelity) et sa personne contr么lante Abigail P. Johnson ont d茅pos茅 le 9e amendement au Schedule 13G le 8 ao没t 2025 pour Taysha Gene Therapies Inc. (TSHA).
- Propri茅t茅 b茅n茅ficiaire : 15 627 821,87 actions ordinaires, repr茅sentant 6,2 % de la classe en circulation au 30 juin 2025.
- Droits de contr么le : Pouvoir de vote exclusif sur 15 622 332 actions et pouvoir discr茅tionnaire exclusif sur la totalit茅 des 15,628 millions ; aucun pouvoir partag茅 de vote ou de disposition n鈥檈st signal茅.
- Statut du d茅p么t : D茅claration faite en vertu de la r猫gle 13d-1(b) en tant que soci茅t茅 m猫re/holding ; la propri茅t茅 est d茅tenue dans le cours normal des affaires sans intention d鈥檌nfluencer le contr么le.
- L鈥檃mendement maintient FMR au-dessus du seuil de d茅claration de 5 %, signalant une exposition institutionnelle importante et continue 脿 TSHA.
FMR LLC (Muttergesellschaft von Fidelity) und deren Kontrollperson Abigail P. Johnson reichten am 08. August 2025 die 脛nderung Nr. 9 zum Schedule 13G 蹿眉谤 Taysha Gene Therapies Inc. (TSHA) ein.
- Wirtschaftliches Eigentum: 15.627.821,87 Stammaktien, was 6,2 % der ausstehenden Aktienklasse zum 30. Juni 2025 entspricht.
- Kontrollrechte: Alleiniges Stimmrecht 眉ber 15.622.332 Aktien und alleiniges Verf眉gungsrecht 眉ber die gesamten 15,628 Millionen; keine gemeinsamen Stimm- oder Verf眉gungsrechte gemeldet.
- Meldepflichtiger Status: Meldung erfolgt gem盲脽 Regel 13d-1(b) als Muttergesellschaft/Holding; das Eigentum wird im gew枚hnlichen Gesch盲ftsverlauf ohne Absicht zur Einflussnahme auf die Kontrolle gehalten.
- Die 脛nderung h盲lt FMR 眉ber der 5 %-Meldegrenze, was auf eine weiterhin bedeutende institutionelle Beteiligung an TSHA hinweist.
- FMR LLC retains a sizable 6.2 % stake, reflecting ongoing institutional confidence in TSHA.
- Sole voting and dispositive authority give the holder flexibility, indicating high conviction.
- None.
Insights
TL;DR: Fidelity still owns 6.2 % of TSHA, signalling sustained institutional support; impact neutral-to-positive.
FMR鈥檚 15.6 M-share stake confirms that one of the world鈥檚 largest asset managers retains a meaningful position in TSHA. While the filing doesn鈥檛 disclose whether the position was raised or trimmed, remaining above the 5 % threshold often underpins liquidity and can reduce free-float volatility. Sole voting and dispositive power allow Fidelity to act quickly on corporate actions, but its 13G (rather than 13D) status indicates passive intent. For investors, the disclosure is supportive but not transformative; fundamentals and clinical progress still dominate the equity story.
TL;DR: Passive 6.2 % holding gives Fidelity influence without activism; governance risk unchanged.
Because FMR files on Schedule 13G, it affirms no immediate plan to influence TSHA鈥檚 strategy or board composition. Nonetheless, Fidelity鈥檚 ability to cast 6 % of votes can be pivotal in close proxy matters. The unchanged passive classification limits near-term governance friction, but management must still consider large-holder preferences on capital allocation and executive comp. Overall governance impact is limited and largely status quo.
FMR LLC (societ脿 madre di Fidelity) e la sua controllante Abigail P. Johnson hanno presentato il Modifica n. 9 al Schedule 13G l'08 agosto 2025 per Taysha Gene Therapies Inc. (TSHA).
- Propriet脿 effettiva: 15.627.821,87 azioni ordinarie, pari al 6,2% della classe in circolazione al 30 giugno 2025.
- Diritti di controllo: Potere di voto esclusivo su 15.622.332 azioni e potere dispositive esclusivo sull'intero ammontare di 15,628 milioni; non 猫 segnalata alcuna autorit脿 condivisa di voto o dispositiva.
- Stato della comunicazione: Segnalazione effettuata ai sensi della Regola 13d-1(b) come societ脿 madre/holding company; la propriet脿 猫 detenuta nell'ordinaria attivit脿 commerciale senza intento di influenzare il controllo.
- La modifica mantiene FMR sopra la soglia di segnalazione del 5%, indicando un'esposizione istituzionale significativa e continuativa a TSHA.
FMR LLC (compa帽铆a matriz de Fidelity) y su persona controladora Abigail P. Johnson presentaron la Enmienda No. 9 al Schedule 13G el 08 de agosto de 2025 para Taysha Gene Therapies Inc. (TSHA).
- Propiedad beneficiaria: 15,627,821.87 acciones comunes, representando el 6.2% de la clase en circulaci贸n al 30 de junio de 2025.
- Derechos de control: Poder exclusivo de voto sobre 15,622,332 acciones y poder exclusivo dispositvo sobre el total de 15.628 millones; no se reporta autoridad compartida de voto o dispositiva.
- Estado de la presentaci贸n: Informe realizado bajo la Regla 13d-1(b) como compa帽铆a matriz/holding; la propiedad se mantiene en el curso ordinario del negocio sin intenci贸n de influir en el control.
- La enmienda mantiene a FMR por encima del umbral de reporte del 5%, se帽alando una exposici贸n institucional material y continua a TSHA.
FMR LLC (Fidelity鞚� 氇殞靷�)鞕� 攴� 歆�氚办瀽 Abigail P. Johnson電� 2025雲� 8鞗� 8鞚� Taysha Gene Therapies Inc. (TSHA)鞐� 雽�頃� Schedule 13G 靾橃爼鞎� 9順�毳� 鞝滌稖頄堨姷雼堧嫟.
- 鞁れ 靻岇湢甓�: 2025雲� 6鞗� 30鞚� 旮办 氤错喌欤� 15,627,821.87欤茧, 氚滍枆 欤检嫕鞚� 6.2%鞐� 頃措嫻頃╇媹雼�.
- 韱奠牅 甓岉暅: 15,622,332欤检棎 雽�頃� 雼弲 鞚橁舶甓岅臣 鞝勳泊 1,562毵� 8觳� 欤检棎 雽�頃� 雼弲 觳橂秳 甓岉暅鞚� 氤挫湢頃橂┌, 瓿惦彊 鞚橁舶甓岇澊雮� 觳橂秳 甓岉暅鞚� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.
- 鞁犼碃 靸來儨: Rule 13d-1(b)鞐� 霐半澕 氇殞靷�/歆赌欤柬殞靷�搿滌劀 鞁犼碃霅橃棃鞙茧┌, 靻岇湢甓岇潃 靷梾鞚� 鞝曥儊鞝侅澑 瓿检爼鞐愳劀 氤挫湢霅橃棃瓿� 韱奠牅鞐� 鞓來枼鞚� 氙胳範 鞚橂弰臧� 鞐嗢姷雼堧嫟.
- 鞚措矆 靾橃爼鞎堨溂搿� FMR鞚� 5% 氤搓碃 旮办靹犾潉 鞙犾頃橃棳 TSHA鞐� 雽�頃� 欷戩殧頃� 旮瓣磤 韴瀽 雲胳稖鞚� 瓿勳啀霅潉 雮橅儉雰呺媹雼�.
FMR LLC (soci茅t茅 m猫re de Fidelity) et sa personne contr么lante Abigail P. Johnson ont d茅pos茅 le 9e amendement au Schedule 13G le 8 ao没t 2025 pour Taysha Gene Therapies Inc. (TSHA).
- Propri茅t茅 b茅n茅ficiaire : 15 627 821,87 actions ordinaires, repr茅sentant 6,2 % de la classe en circulation au 30 juin 2025.
- Droits de contr么le : Pouvoir de vote exclusif sur 15 622 332 actions et pouvoir discr茅tionnaire exclusif sur la totalit茅 des 15,628 millions ; aucun pouvoir partag茅 de vote ou de disposition n鈥檈st signal茅.
- Statut du d茅p么t : D茅claration faite en vertu de la r猫gle 13d-1(b) en tant que soci茅t茅 m猫re/holding ; la propri茅t茅 est d茅tenue dans le cours normal des affaires sans intention d鈥檌nfluencer le contr么le.
- L鈥檃mendement maintient FMR au-dessus du seuil de d茅claration de 5 %, signalant une exposition institutionnelle importante et continue 脿 TSHA.
FMR LLC (Muttergesellschaft von Fidelity) und deren Kontrollperson Abigail P. Johnson reichten am 08. August 2025 die 脛nderung Nr. 9 zum Schedule 13G 蹿眉谤 Taysha Gene Therapies Inc. (TSHA) ein.
- Wirtschaftliches Eigentum: 15.627.821,87 Stammaktien, was 6,2 % der ausstehenden Aktienklasse zum 30. Juni 2025 entspricht.
- Kontrollrechte: Alleiniges Stimmrecht 眉ber 15.622.332 Aktien und alleiniges Verf眉gungsrecht 眉ber die gesamten 15,628 Millionen; keine gemeinsamen Stimm- oder Verf眉gungsrechte gemeldet.
- Meldepflichtiger Status: Meldung erfolgt gem盲脽 Regel 13d-1(b) als Muttergesellschaft/Holding; das Eigentum wird im gew枚hnlichen Gesch盲ftsverlauf ohne Absicht zur Einflussnahme auf die Kontrolle gehalten.
- Die 脛nderung h盲lt FMR 眉ber der 5 %-Meldegrenze, was auf eine weiterhin bedeutende institutionelle Beteiligung an TSHA hinweist.
FAQ
How many TSHA shares does FMR LLC currently own?
What percentage of Taysha Gene Therapies鈥� outstanding shares does this represent?
Does FMR LLC have voting control over these shares?
Is Fidelity鈥檚 position considered active or passive?
Who signed the filing on behalf of FMR LLC and Abigail P. Johnson?
